Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
105 participants
INTERVENTIONAL
2001-11-30
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Budesonide for Induction of Remission in Incomplete Microscopic Colitis
NCT02142634
Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis
NCT05915104
Budesonide Treatment for Lymphocytic Colitis
NCT00180050
Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis
NCT00217022
Budesonide for Maintenance Treatment of Collagenous Colitis
NCT00180076
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Budesonide
Budesonide 9mg
Budesonide
Budesonide 9 mg
bismuth
Bismuth mixture
Bismuth
Bismuth mixture
Fiber
Fiber preparation
Fiber
Fiber for control
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Budesonide
Budesonide 9 mg
Bismuth
Bismuth mixture
Fiber
Fiber for control
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Symptoms to such an extent that treatment is indicated
* Age \> 17 years
* Informed consent
Exclusion Criteria
* Patients treated with ketoconazole
* Pregnant and breast-feeding females
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Norwegian University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Per G Farup, PhD
Role: STUDY_CHAIR
Norwegian University of Science and Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aust-Agder Sentralsjukehus
Arendal, , Norway
Sykehuset Innlandet HF, Gjøvik
Gjøvik, , Norway
Sykehuset Innlandet, HF, Hamar
Hamar, , Norway
Sykehuset Innlandet HF, Lillehammer
Lillehammer, , Norway
Helse NordMøre og Romsdal
Molde, , Norway
Akershus Universitetssykehus
Nordbyhagen, , Norway
Aker sykehus
Oslo, , Norway
Rikshopitalet
Oslo, , Norway
St. Olavs Hospital
Trondheim, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SLV 01-07035
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.